Sarcomas

Sarcomas are malignant tumors of mesenchymal origin comprising more than 70 distinct histologic subtypes. Soft tissue sarcomas account for ~13,590 new cases/year in the US; osteosarcoma and Ewing sarcoma are the most common primary bone sarcomas in children and young adults. Anthracycline-based chemotherapy (doxorubicin ± ifosfamide) is the systemic backbone. Histology-specific therapies — trabectedin for liposarcoma/leiomyosarcoma, eribulin for liposarcoma, tazemetostat for INI1-negative epithelioid sarcoma, and imatinib for GIST/DFSP — reflect the importance of molecular subtyping.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Sarcomas

• Doxorubicin (Adriamycin) — Anthracycline
• Ifosfamide (Ifex) — Alkylating Agent
• Gemcitabine (Gemzar) — Antimetabolite
• Docetaxel (Taxotere) — Taxane
• Paclitaxel (Taxol) — Taxane
• Eribulin (Halaven) — Other
• Pazopanib (Votrient) — Tyrosine Kinase Inhibitor
• Imatinib (Gleevec) — Tyrosine Kinase Inhibitor
• Tazemetostat (Tazverik) — Other